Drug Profile
AGI 101H
Alternative Names: AGI-101Latest Information Update: 10 Sep 2018
Price :
$50
*
At a glance
- Originator AGIRx
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 10 Sep 2018 Discontinued - Phase-II for Malignant melanoma (Inoperable/Unresectable, Late-stage disease) in Poland (Parenteral)
- 10 Sep 2018 Discontinued - Phase-II for Malignant melanoma (Late-stage disease, Adjuvant therapy) in Poland (Parenteral)
- 21 Apr 2016 AGIRx terminates a phase I/II trial in Malignant melanoma in Poland (NCT00716495)